Clinical trial · Interventional
Evaluation of the Pharmacokinetics, Safety, and Tolerability of IM Letrozole LEBE in Healthy Post-menopausal Women
A Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole LEBE at Different Strengths in Voluntary Healthy Post-Menopausal Women.
NCT06315205CI-TRIAL-00119343LEILA-1completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I, open label, sequential, single ascending dose (SAD) study to evaluate the pharmacokinetic (PK), safety, and tolerability of Letrozole LEBE in healthy post-menopausal women.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Healthy | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Letrozole LEBE 150 mg | Drug | — | UNRESOLVED |
| Letrozole LEBE 225 mg | Drug | — | UNRESOLVED |
| Letrozole LEBE 75 mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Cohort 1: Letrozol LEBE 75 mg
- interventionNames
- Drug: Letrozole LEBE 75 mg
- type
- EXPERIMENTAL
- label
- Cohort 2: Letrozol LEBE 150 mg
- interventionNames
- Drug: Letrozole LEBE 150 mg
- type
- EXPERIMENTAL
- label
- Cohort 3: Letrozol LEBE 225 mg
- interventionNames
- Drug: Letrozole LEBE 225 mg
Primary outcomes (8)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Healthy post-menopausal women. * Capable of providing informed consent. * Weight of ≥50 kg and a BMI ≥19 and ≤39 kg/m2. * Subjects should be able to communicate with clinic staff. Exclusion Criteria: * Subjects who have a history of allergy or hypersensitivity to letrozole or any of the inactive ingredients. * Subjects who have a history of galactose intolerance, severe hereditary lactase deficiency glucose-galactose malabsorption. * Subjects who have used estrogen or progesterone hormone replacement therapy, thyroid replacement therapy, oral contraceptives, androgens, luteinizing hormone (LH) releasing hormone analogs, prolactin inhibitors, or antiandrogens within prior to Screening. * Subjects who have used: any medications including St. John's wort or any medications or products known to be potent or moderate inhibitors of CYP P450 3A4. * Subjects who have been diagnosed with osteoporosis. * Subjects who have an abnormality at Screening or prior to first dose that in the opinion of the investigator increases the risk of participating in the study. * Subjects who have any clinically significant abnormal physical examination or laboratory safety findings at screening. * Subjects who have relevant diseases or clinically significant abnormal relevant findings at Screening, as determined by medical history, physical examination, laboratory, ECG, DEXA, and breast and pelvic examination. * Subjects who have history of any significant chronic disease. * History of cancer within the past 5 years with the exception of non-melanoma skin cancer. * Subjects who have a history of drug-dependence, and recent history of alcoholism or abuse of alcohol. * Subjects who have received a drug in research or have participated in other clinical trials within 90 days, prior to dosing. * Any other unspecified reason that, in the opinion of the investigator (or designee) or sponsor, makes the subject unsuitable for enrolment.
References
Publications (0)
Data not yet available
No reference posted for this study.